editions:LCCN2007414498 - Google grāmatas

An exact determination of the risk of serious and fatal blood dyscrasias is not possible because of lack of accurate information regarding (1) the size of the population at risk, (2) the total number of drug-associated dyscrasias, and (3) the total number...

Drug Efficacy: Hearings Before a Subcommittee of the Committee on Government ... - 65. lappuse
autors: United States. Congress. House. Committee on Government Operations. Intergovernmental Relations Subcommittee - 1970 - 415 lapas
Pilnskats - Par šo grāmatu

Competitive Problems in the Drug Industry: Hearings Before Subcommittee on ...

United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly - 1975 - 888 lapas

...regarding 1 ) the size of the population at risk, 2} the total number of drug-associated dyscra\ios, and 3) the total number of non-drug associated dyscrasias....and the State Department of Public Health in January 1997. the risk of fatal aplastic anemia was estimated at 1:24,200 to 1:40.500 based on two dosage levels....

Pilnskats - Par šo grāmatu

Competitive Problems in the Drug Industry, 11-12. sējumi

United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly - 1969 - 1012 lapas

...the population at risk, 2) the total number of drug-associated dyscrasias, and 3) the total number or non-drug associated dyscrasias. In a report to the...Association and the State Department of Public Health En January 1967, the risk of fata! aplastic anemia was estimated at 1:24.200 to 1:40,500 based on two...

Pilnskats - Par šo grāmatu

Competitive problems in the drug industry: hearings before Subcommittee on ...

United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly and Anticompetitive Activities, United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly - 1975 - 1360 lapas

...time was considered to be one in 800,000. A recent report to the California State Assembly and Senate by the California Medical Association and the State Department of Public Health, has revealed that the risk, on the basis of an average dose of 7.5 grams, is 1 in 24,000. Dr. Lueck....

Pilnskats - Par šo grāmatu

Competitive Problems in the Drug Industry, 4. sējums;6. sējums

United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly - 1968 - 638 lapas

Pilnskats - Par šo grāmatu

Competitive Problems in the Drug Industry, 6-7. daļas

United States. Congress. Senate. Select Committee on Small Business. Subcommittee on Monopoly - 1968 - 1020 lapas

Pilnskats - Par šo grāmatu

U.S. Export of Banned Products: Hearings Before a Subcommittee of the ...

United States. Congress. House. Committee on Government Operations. Commerce, Consumer, and Monetary Affairs Subcommittee - 1978 - 278 lapas

...the aiz" of th* population at risk, (b) the total r.-.aiber of drug-associated dys-rasias, and '.:'} the total number of nondrug associated dyscrasias....to the California State Assembly by the California, 'ledical Asss:1ation and the State Department of Public Health Ir. January 1967, the rls's of fatal...

Pilnskats - Par šo grāmatu

U.S. Export of Banned Products: Hearings Before a Subcommittee of the ...

United States. Congress. House. Committee on Government Operations. Commerce, Consumer, and Monetary Affairs Subcommittee - 1978 - 272 lapas

...at risk, (b) the total r.-abur of drug-associated dyx-rasiax, anrt {c} the total nuober of nondrog associated dyscrasias. In a report to the California State Assembly by the California. Medical Assssiation and the State Departzer.t of Public Eealth ir. January 19fi7, the risk of fatal aplastio...

Pilnskats - Par šo grāmatu